Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once-weekly vs daily Norditropin in growth hormone deficiency in children
NCT02616562Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2016
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 2 trial of somapacitan in growth hormone deficiency (GHD), sponsored by Novo Nordisk. Started Mar 2016; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02616562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616562.